Sutro Biopharma (STRO)

• Market cap: $75.4M
• 1 day: 20.04%
• 5 days: 19.02%
• 1 month: 61.39%
• 3 months: -46.15%
• 6 months: -70.51%
• Year to date: -45.60%
• 1 year: -69.12%
• 5 years: -93.86%
• 10 years: -93.86%
• Sector: Healthcare
• Industry: Biotechnology

About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Employees: 310

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

263% more call options, than puts

Call options by funds: $243K | Put options by funds: $67K

11% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 36

1.0% more ownership

Funds ownership: 76.28% [Q3] → 77.28% (+1.0%) [Q4]

6% less funds holding

Funds holding: 130 [Q3] → 122 (-8) [Q4]

20% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 30

46% less capital invested

Capital invested by funds: $216M [Q3] → $117M (-$99.1M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1 5% downside
• Avg. target: $1.75 67% upside
• High target: $2 90% upside

4 analyst ratings

• positive: 0 0%
• neutral: 3 75%
• negative: 1 25%

HC Wainwright & Co. Andres Maldonado 28% 1-year accuracy 15 / 53 met price target	90% upside $2	Neutral Reiterated	29 Apr 2025
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 354 met price target	90% upside $2	Neutral Downgraded	17 Mar 2025
Wedbush David Nierengarten 40% 1-year accuracy 46 / 114 met price target	90% upside $2	Neutral Downgraded	14 Mar 2025
B of A Securities Tazeen Ahmad 28% 1-year accuracy 9 / 32 met price target	5% downside $1	Underperform Downgraded	14 Mar 2025